NCT01582191 2025-10-27Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic CancerM.D. Anderson Cancer CenterPhase 1 Completed151 enrolled
NCT01496313 2025-10-03To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerSanofiPhase 4 Completed81 enrolled 15 charts
NCT00410761 2025-09-24An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerSanofiPhase 3 Completed331 enrolled 15 charts
NCT01298323 2025-04-24Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib TreatmentSanofiPhase 3 Completed205 enrolled 9 charts
NCT04211337 2025-04-20LIBRETTO-531Eli Lilly and CompanyPhase 3 Active not recruiting291 enrolled 16 charts 1 FDA